Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna shares surged following trial results for a personalized mRNA melanoma vaccine developed with Merck.
Who reported it (7)
- Moderna shares surge as melanoma vaccine with Merck succeeds in large trial CNN · 3h ago
- Cancer treatment could face landmark moment with promising vaccine The Washington Post · 3h ago
- Moderna-Merck MRNA Shot Helped Cut Melanoma Recurrence in Big Trial Bloomberg.com · 3h ago
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial CNBC · 3h ago
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT · 3h ago
- World in Brief: trials show promise for a skin-cancer vaccine; Trump pauses Canada tariffs The Economist · 3h ago
- Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma NBC News · 3h ago broke it first
What happened
The treatment helped cut melanoma recurrence, described by coverage as a potential landmark moment for cancer treatment and skin-cancer vaccine development. Coverage emphasizes the involvement of both companies and the specific focus on preventing the recurrence of melanoma.
Coverage does not yet specify the full timeline for regulatory approval or commercial availability, nor do the headlines establish what future steps the companies will take with the vaccine data.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (60% supported) Updated 43m ago.
Questions people are asking
Which companies developed the melanoma vaccine?
Moderna and Merck developed the personalized mRNA melanoma vaccine.
What type of trial did the vaccine succeed in?
The vaccine succeeded in a large, late-stage trial for melanoma.
What effect did the shot have on patients?
The shot helped cut melanoma recurrence and showed promise in preventing the return of the disease.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
Column | 3 minutes of this activity may cut the risk of 13 cancers, study finds
A three‑minute burst of vigorous movement could slash the odds of thirteen cancers, upending the idea that only long workouts protect health.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Merck raised its sales forecast while cutting profit guidance following recent acquisition charges.
First person gets new experimental vaccine for Ebola
The world's first vaccine targeting the Bundibugyo ebolavirus has entered human clinical trials following the first volunteer vaccination.
Creatine supplements may help halt cancer growth, study suggests
Scientific research into the impact of creatine supplementation on cancer development is sparking conflicting reports regarding its potential risks and benefits.
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.